Rationale, design, and baseline characteristics of the Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection: EPIC-HIV Randomized Clinical Trial

By afschroeder • March 3, 2026

Durstenfeld MS, Levkova-Clark M, Ms DL, Schaffer V, Abohashem S, Ma Y, Kawai K, Lu MT, Sereti I, Deeks SG, Tawakol A, Hsue PY. Rationale, design, and baseline characteristics of the Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection: EPIC-HIV Randomized Clinical Trial. Am Heart J. 2026 Feb 28:107400. doi: 10.1016/j.ahj.2026.107400. Epub ahead of print. PMID: 41771366.

Tags: arterial inflammation, Cardiology/Epi, Cholesterol, Clinical Trial, Coronary Atherosclerosis, HIV, PCSK9, Publications

ENPP1 blockade with a humanized monoclonal antibody enhances renal repair after acute kidney injury

Su L, Sun Q, Zhou Z, Wang R, Wang J, Alvarez JF, Tao B, Das K, Zhou Q, Wang J, Zhang G, Ten Hoeve J,[...]

Electrophysiological Effects of Right and Left Tragus Nerve Stimulation in Humans

Olarte N, Nguyen H, Krokhaleva Y, Khakpour H, Do D, Hayase J, Macias C, Stavrakis S, Vaseghi M. Electrophysiological Effects of Right and Left Tragus[...]

Purulent Pericarditis and Tamponade From a Migrating Esophageal Foreign Body

Hindosh ZR, Cha BM, Soverow J, Nguyen K. Purulent Pericarditis and Tamponade From a Migrating Esophageal Foreign Body. JACC Case Rep. 2026 Jun 13:108754. doi:[...]